% alzhub.org library filter
% Source: https://alzhub.org/research?author=O%27Gorman+J
% 6 entries, in the order the page lists them. Built from alzhub.org's own records.
% 0 entries have no readable author in the source record and carry no author field.

@article{shulman2023-38012285,
  author  = {Shulman, M. and Kong, J. and O'Gorman, J. and Ratti, E. and Rajagovindan, R. and Viollet, L. and Huang, E. and Sharma, S. and others},
  title   = {{TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer's disease}},
  journal = {Nature aging},
  year    = {2023},
  doi     = {10.1038/s43587-023-00523-w},
  pmid    = {38012285},
  url     = {https://doi.org/10.1038/s43587-023-00523-w}
}

@article{chen2024-38567735,
  author  = {Chen, T. and O'Gorman, J. and Castrillo-Viguera, C. and Rajagovindan, R. and Curiale, G. G. and Tian, Y. and Patel, D. and von Rosenstiel, P. and others},
  title   = {{Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumab}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2024},
  doi     = {10.1002/alz.13755},
  pmid    = {38567735},
  url     = {https://doi.org/10.1002/alz.13755}
}

@article{chiao2019-29777003,
  author  = {Chiao, P. and Bedell, B. J. and Avants, B. and Zijdenbos, A. P. and Grand'Maison, M. and O'Neill, P. and O'Gorman, J. and Chen, T. and others},
  title   = {{Impact of Reference and Target Region Selection on Amyloid PET SUV Ratios in the Phase 1b PRIME Study of Aducanumab}},
  journal = {Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year    = {2019},
  doi     = {10.2967/jnumed.118.209130},
  pmid    = {29777003},
  url     = {https://doi.org/10.2967/jnumed.118.209130}
}

@article{loomis2024-38165296,
  author  = {Loomis, S. J. and Miller, R. and Castrillo-Viguera, C. and Umans, K. and Cheng, W. and O'Gorman, J. and Hughes, R. and Budd Haeberlein, S. and others},
  title   = {{Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies}},
  journal = {Neurology},
  year    = {2024},
  doi     = {10.1212/wnl.0000000000207919},
  pmid    = {38165296},
  url     = {https://doi.org/10.1212/wnl.0000000000207919}
}

@article{ferrero2016-29067304,
  author  = {Ferrero, J. and Williams, L. and Stella, H. and Leitermann, K. and Mikulskis, A. and O'Gorman, J. and Sevigny, J.},
  title   = {{First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease}},
  journal = {Alzheimer's \& dementia (New York, N. Y.)},
  year    = {2016},
  doi     = {10.1016/j.trci.2016.06.002},
  pmid    = {29067304},
  url     = {https://doi.org/10.1016/j.trci.2016.06.002}
}

@article{buddhaeberlein2017-29181491,
  author  = {Budd Haeberlein, S. and O'Gorman, J. and Chiao, P. and Bussière, T. and von Rosenstiel, P. and Tian, Y. and Zhu, Y. and von Hehn, C. and others},
  title   = {{Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2017},
  doi     = {10.14283/jpad.2017.39},
  pmid    = {29181491},
  url     = {https://doi.org/10.14283/jpad.2017.39}
}